Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies

Last Updated: Tuesday, May 13, 2025

A phase I study evaluating the safety of ROR1 CAR T cells. The researchers observed antitumor activity in chronic lymphocytic leukemia, but this was limited in triple-negative breast cancer and non–small cell lung cancer. The ROR1 CAR-T cells were well tolerated in most patients, although there was one dose-limiting toxicity at dose level 4 in a patient with advanced non–small cell lung cancer.

Clinical Cancer Research

Blood Advances

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Journal of Clinical Oncology

Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma

Cancer Cell

Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia

Pediatric Blood & Cancer

Neuropsychological functioning in pediatric patients with leukemia or lymphoma treated with CAR T-cell therapy: A retrospective chart review

Leukemia

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Brain

Current state and perspectives of CAR T-cell therapy in central nervous system diseases

Clinical Cancer Research

Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies

Blood

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Oncogene

Preclinical application of a CD155 targeting chimeric antigen receptor T-cell therapy for digestive system cancers

Critical Reviews in Oncology/Hematology

Chimeric antigen receptor T cell immunotherapy for gynecological malignancies

CAR T-Cell Therapy Resource Center

Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies

Blood Advances

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Journal of Clinical Oncology

Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma

Cancer Cell

Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia

Pediatric Blood & Cancer

Neuropsychological functioning in pediatric patients with leukemia or lymphoma treated with CAR T-cell therapy: A retrospective chart review

Leukemia

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Brain

Current state and perspectives of CAR T-cell therapy in central nervous system diseases

Clinical Cancer Research

Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies

Blood

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Oncogene

Preclinical application of a CD155 targeting chimeric antigen receptor T-cell therapy for digestive system cancers

Critical Reviews in Oncology/Hematology

Chimeric antigen receptor T cell immunotherapy for gynecological malignancies

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

Fast Facts #12: BCMA Targets